Measures liver fat before and after chemotherapy using AI scans
Uses AI to measure liver fat in cancer patients before and after chemotherapy.
Plain-language title generated from the registry record
Registry title: Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
Key facts
- Where
- Kunming, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who are having chemotherapy before or after surgery and whose liver shows no fatty liver on CT or ultrasound. It uses MRI scans to measure changes in liver fat.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- CT or B ultrasound showed no fatty liver.
- Earlier treatment
- Must have received neoadjuvant or adjuvant chemotherapy.
Main reasons for not taking part
- MRI contraindications such as a pacemaker, stent, metal implant or claustrophobia
- Missing follow-up information
- Liver lesions such as metastases or hemangioma
- Poor image quality
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06735118, who can take part
Where in China
- Yunnan Cancer HospitalKunming, ChinaContact: Guojun Zhang, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yunnan Cancer Hospital
- Trial code
- NCT06735118
- Record updated
- 16 December 2024
- Original description
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.Read full original descriptionShow less
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.
The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.
Inclusion: CT/B ultrasound showed no fatty liver; No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia; Received neoadjuvant/adjuvant chemotherapy.
Exclusion: Missing follow-up information; Liver lesions (metastases, hemangioma, etc.); Poor image quality.